Screener
Veracyte VCYT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of deferred revenue | 749 | 1,160 |
| Current portion of acquisition-related contingent consideration | 982 | 1,332 |
| Current portion of operating lease liabilities | 4,347 | 4,051 |
| Total current liabilities | 56,115 | 59,937 |
| Deferred tax liabilities | 636 | 646 |
| Acquisition-related contingent consideration, net of current portion | 257 | 257 |
| Operating lease liabilities, net of current portion | 34,986 | 35,603 |
| Total liabilities | 91,994 | 96,443 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's total current liabilities?
- Veracyte (VCYT) reported total current liabilities of $56.12M in Q1 2026.
- How has Veracyte's total current liabilities changed year-over-year?
- Veracyte's total current liabilities decreased by 25.3% year-over-year, from $75.13M to $56.12M.
- What is the long-term trend for Veracyte's total current liabilities?
- Over 5 years (2020 to 2025), Veracyte's total current liabilities has grown at a 29.0% compound annual growth rate (CAGR), from $16.78M to $59.94M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Veracyte's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude